BERGENBIO ANNOUNCES TOP LINE DATA FROM PHASE II TRIAL ASSESSING BEMCENTINIB IN HOSPITALISED COVID-19 PATIENTS
The trial BGBC020 shows that Bemcentinib has the potential to increase the rate of ventilator free survival in more than 50% of hospitalised COVID-19 patients, addressing the greatest challenge faced by hospitals worldwide fighting the pandemic. · Ventilator Free Survival observed in 90% in bemcentinib treated patients vs 72% in SOC treated patients, in a subgroup of patients with increased disease severity · Survival benefit numerically greater in bemcentinib treated patients · Bemcentinib anti-viral mechanism of action supported by analysis · Bemcentinib was well tolerated